IP Library Granted Patent US 9,040,484
Granted Patent B2
US 9,040,484 · App. 14/112,444 · Granted May 26, 2015

Production and delivery of a stable collagen

Inventors: M. Peter Marinkovich (Redwood City, CA); Alfred T. Lane (Los Altos, CA); Jayakumar Rajadas (Cupertino, CA)
Assignees: The Board of Trustees of the Leland Stanford Junior University; Department of Veterans Affairs
A61M37/0015A61K38/39C07K14/78C12N15/67C12N9/0071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,484
App. No.
14/112,444
Granted
May 26, 2015
Kind
B2
Abstract

Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.

Claims (11)

1. A method of synthesizing collagen VII, the method comprising:

synthesizing recombinant collagen VII in a host cell that has been genetically modified to increase expression of prolyl-4-hydroxylase, wherein the genetic modification to increase expression of prolyl-4-hydroxylase comprises (i) introduction into the cell of an episomal vector comprising a genetic sequence encoding prolyl-4-hydroxylase operably linked to a promoter, or (ii) modifying the genomic sequence of an endogenous prolyl-4-hydroxylase in said cell to increase expression;

wherein recombinantly produced collagen VII has increased stability relative to a collagen produced in a comparable host cell lacking said genetic modification.

2. The method of claim 1 , wherein said episomal vector further comprises a genetic sequence encoding collagen VII operably linked to a promoter.

3. The method of claim 1 , wherein one or both of said collagen VII and said prolyl-4-hydroxylase are human.

4. The method of claim 1 , wherein said host cell is a mammalian cell.

5. The method of claim 1 , further comprising the step of isolating said collagen VII from said cell.

6. The method of claim 5 , further comprising the step of administering said collagen VII to an individual in need thereof.

7. The method of claim 6 , wherein said administration is intradermal.

8. The method of claim 6 , wherein said individual suffers from epidermolysis bullosa.

9. The method of claim 8 , wherein said epidermolysis bullosa is the result of a genetic defect in collagen VII.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2015
From: MARINKOVICH, PETER M.
To: DEPARTMENT OF VETERANS AFFAIRS; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 035474/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2013
From: MARINKOVICH, M. PETER; RAJADAS, JAYAKUMAR; LANE, ALFRED T.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 031834/0767 →
CONFIRMATORY LICENSE Recorded Dec 13, 2013
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031815/0138 →
Continuity (2)
Provisional Application 61479068 · Apr 26, 2011
Related Publication 20140107036A1 · Apr 17, 2014